JP2005535582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535582A5 JP2005535582A5 JP2004500844A JP2004500844A JP2005535582A5 JP 2005535582 A5 JP2005535582 A5 JP 2005535582A5 JP 2004500844 A JP2004500844 A JP 2004500844A JP 2004500844 A JP2004500844 A JP 2004500844A JP 2005535582 A5 JP2005535582 A5 JP 2005535582A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- weight
- amount
- present
- fenofibrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 17
- 229960002297 fenofibrate Drugs 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 239000004067 bulking agent Substances 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000004606 Fillers/Extenders Substances 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000000337 buffer salt Substances 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- -1 fenofibrate phospholipid Chemical class 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims 6
- 239000006186 oral dosage form Substances 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000005913 Maltodextrin Substances 0.000 claims 2
- 239000007900 aqueous suspension Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000725 suspension Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37723702P | 2002-05-03 | 2002-05-03 | |
| PCT/US2003/013865 WO2003092659A1 (en) | 2002-05-03 | 2003-05-02 | Oral dosage forms comprising fenofibrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535582A JP2005535582A (ja) | 2005-11-24 |
| JP2005535582A5 true JP2005535582A5 (https=) | 2010-08-12 |
Family
ID=29401461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500844A Pending JP2005535582A (ja) | 2002-05-03 | 2003-05-02 | 被覆錠剤 |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP1517676A1 (https=) |
| JP (1) | JP2005535582A (https=) |
| AU (1) | AU2003225285A1 (https=) |
| CA (1) | CA2484375C (https=) |
| WO (1) | WO2003092659A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI358407B (en) * | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| WO2008002568A2 (en) * | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
| FR2940118B1 (fr) * | 2008-12-24 | 2013-08-09 | Ethypharm Sa | Formulation pharmaceutique de fenofibrate nanonise |
| WO2010102065A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
| WO2010111132A2 (en) | 2009-03-27 | 2010-09-30 | Bend Research, Inc. | Spray-drying process |
| PT2611530T (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Aparelho de secagem por pulverização e métodos de utilização do mesmo |
| US9084976B2 (en) | 2010-09-03 | 2015-07-21 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
| US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
| WO2012040502A1 (en) | 2010-09-24 | 2012-03-29 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
| WO2016067132A1 (en) | 2014-10-31 | 2016-05-06 | Bend Research Inc. | Process for forming active domains dispersed in a matrix |
| WO2016196648A1 (en) * | 2015-06-01 | 2016-12-08 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
| CN106552266A (zh) * | 2015-09-25 | 2017-04-05 | 英创远达制药公司 | 一种美法仑口服制剂 |
| CA3187241A1 (en) * | 2020-08-03 | 2022-02-10 | Krishna Murthy Bhavanasi | Pharmaceutical compositions comprising ribociclib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| WO2002024193A1 (en) * | 2000-09-20 | 2002-03-28 | Skyepharma Canada Inc. | Stabilised fibrate microparticles |
| FR2819720B1 (fr) * | 2001-01-22 | 2004-03-12 | Fournier Lab Sa | Nouveaux comprimes de fenofibrate |
-
2003
- 2003-05-02 EP EP03722005A patent/EP1517676A1/en not_active Ceased
- 2003-05-02 EP EP10000401A patent/EP2228060A1/en not_active Withdrawn
- 2003-05-02 WO PCT/US2003/013865 patent/WO2003092659A1/en not_active Ceased
- 2003-05-02 AU AU2003225285A patent/AU2003225285A1/en not_active Abandoned
- 2003-05-02 JP JP2004500844A patent/JP2005535582A/ja active Pending
- 2003-05-02 CA CA2484375A patent/CA2484375C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535582A5 (https=) | ||
| AU623177B2 (en) | Granular pharmaceutical formulations | |
| EP0527637B1 (en) | Spheroids containing dittiazem and a spheronizing agent | |
| TWI540128B (zh) | 醫藥組合物 | |
| ES2322896T3 (es) | Formulaciones farmaceuticas con biodisponibilidad mejorada. | |
| TWI583384B (zh) | 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物 | |
| US20040228915A1 (en) | Oral extended release compressed tablets of multiparticulates | |
| JPH0768125B2 (ja) | 酸不安定化合物の内服用製剤 | |
| US20090124702A1 (en) | Pharmaceutical Compositions of Metformin | |
| JPH09502740A (ja) | プロトンポンプ抑制剤を含有する複数単位の製剤 | |
| KR20140135216A (ko) | 다비가트란 이텍실레이트의 경구형 약학 조성물 | |
| US20040101565A1 (en) | Mehtod to obtain microparticles containing a h+ k+ atp-ase inhibitor | |
| JP2005506987A5 (https=) | ||
| JP2013534242A (ja) | ナルブフィンを含有する製剤及びそれらの使用 | |
| CA2765522A1 (en) | Solid pharmaceutical composition of edoxaban having improved solubility | |
| US20130216617A1 (en) | Pharmaceutical compositions of (r)-lansoprazole | |
| EP1061803B1 (en) | Compositions of eprosartan | |
| US20060153925A1 (en) | Novel solid pharmaceutical composition comprising amisulpride | |
| CA2484375A1 (en) | Oral dosage forms comprising fenofibrate | |
| ES2321980T3 (es) | Composicion farmaceutica de liberacion controlada que contiene carvedilol. | |
| WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
| CN101854921B (zh) | 用于口服施用ppi的药物制剂 | |
| CN1681493A (zh) | 掩味舒马曲坦片剂及其制备方法 | |
| US20030022928A1 (en) | Novel compositions of eprosartan | |
| JP2005513037A (ja) | ５−［４−［２−（ｎ−メチル−ｎ−（２−ピリジル）アミノ）エトキシ］ベンジル］チアゾリジン−２，４−ジオンおよび当該化合物配合の医薬組成物 |